New treatments for acromegaly: Is a revolution underway? - 03/04/25

Doi : 10.1016/j.ando.2025.101710

Justine Cristante ^a, Frédéric Castinetti ^b,^⁎
^a Université Grenoble Alpes, CHU Grenoble Alpes, Inserm, CEA, IRIG Biosanté, 38000 Grenoble, France
^b Aix-Marseille Université, Inserm, MMG, Department of Endocrinology, La Conception Hospital, Assistance publique–Hôpitaux de Marseille, Marseille, France

^⁎Corresponding author. La Conception Hospital, 147, boulevard Baille, 13385 Marseille cedex 05, France.La Conception Hospital147, boulevard BailleMarseille cedex 0513385France

Abstract

The first-line treatment for acromegaly is transsphenoidal surgery. Somatostatin receptor ligands are usually prescribed if surgery fails, or, in some patients, as pre-surgical medical treatment. The efficacy and tolerance of first-generation somatostatin receptor ligands is well established, but they incur unmet medical needs due to their mode of administration and side effects. We report results for new compounds that may be used in the near future as alternatives to first-generation somatostatin receptor ligands, with data on efficacy and tolerance: oral octreotide, paltusotine and long-acting subcutaneous octreotide are reviewed in detail, together with potential new compounds under investigation. We also discuss their potential role in the therapeutic armamentarium for acromegaly.

Le texte complet de cet article est disponible en PDF.

Keywords : Acromegaly, Octreotide, Lanreotide, Paltusotine, Transsphenoidal surgery